Genipin and UV-CLX is safe and effective for keratoconus

Article

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus, claims a study in Molecular Vision.

Dr Marcel Y. Avila et al., Department of Ophthalmology, Facultad de Medicina, Universidad Nacional de Colombia, Bogota, Colombia, separated porcine eyes into three groups comprising genipin 0.25% UV-CLX (clinical crosslinking procedure), a glutaraldehyde 0.1% (gold standard crosslinker) and control.

A pressure sensor cannulated to the anterior chamber continuously monitored all groups. Changes in ocular pressure due to ocular volume were evaluated. The exponential of polynomial quadratic fit was used to calculate ocular rigidity. A viability assay with alizarin red staining was used to assess endothelial damage.

In the genpin and UV-CLX globes where the cornea was stiffened there were significant changes in IOP. Mean ocular rigidity coefficient was 0.0078 mmHg/μL for genpin, 0.0065 mmHg/μL for UV-CLX, 0.0092 mmHg/μL for glutaraldehide and 0.0046 mmHg/μL for control eyes.

In the control group endothelial damage was 5.9±1.8%, 10.3±1.7% in UV-CLX, 9.4±1.5% in Genipin 0.25% and 40.1±6.2% in glutaraldehide. In the UV-CLX group there was a significant reduction of keratocites.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.